Related Experiment Video
Updated: Jun 18, 2026
06:27
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
Prevention of type 1 diabetes
Diane K Wherrett1, Denis Daneman
1Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Ontario, Canada.
Endocrinology and Metabolism Clinics of North America
|December 1, 2009
Summary
Preventing beta-cell loss in type 1 diabetes is crucial. Current research focuses on immunomodulatory agents and clinical trials, with some agents showing promise shortly after diagnosis but no pre-diagnosis benefits yet.
Area of Science:
- Immunology
- Endocrinology
- Diabetes Research
Background:
- Type 1 diabetes involves autoimmune destruction of insulin-producing beta cells.
- Identifying individuals at risk and preserving residual beta-cell function are key research objectives.
- Advances in understanding genetic susceptibility and immunomodulation are driving new therapeutic strategies.
Purpose of the Study:
- To review current strategies and clinical trial progress in preventing beta-cell loss in type 1 diabetes.
- To categorize interventions based on the stage of disease: primary, secondary, and tertiary prevention.
- To assess the efficacy of existing and emerging treatments for beta-cell preservation.
Main Methods:
- Review of recent scientific literature and ongoing clinical trials.
- Analysis of intervention strategies targeting different stages of type 1 diabetes development.
- Evaluation of immunomodulatory agents and their impact on beta-cell survival.
Main Results:
- Several agents demonstrate potential benefits when administered shortly after type 1 diabetes diagnosis (tertiary prevention).
- No interventions have proven effective in preventing the onset of autoimmunity (primary prevention).
- Significant progress has been made in predicting risk and understanding disease mechanisms.
Conclusions:
- Tertiary prevention strategies show promise for preserving residual beta cells post-diagnosis.
- Further research is needed for effective primary and secondary prevention of type 1 diabetes.
- International collaborations are accelerating knowledge and therapeutic development in this field.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.